| |
Death at 1 year
|
Total (N = 153)
|
|---|
|
No (N = 67)
|
Yes (N = 86)
|
|---|
|
Age (years)
|
60.00 (38.50–68.50)
|
63.00 (50.25–70.00)
|
61 (46–69)
|
|
Male
|
45 (67.2)
|
60 (69.8)
|
105 (69)
|
|
G6PD deficiency
|
7 (10.4)
|
2 (2.3)
|
9 (6)
|
|
Underlying malignancy
| | | |
|
Solid cancer
|
0 (0)
|
2 (2.3)
|
2 (1)
|
|
Leukemia
|
23 (34.3)
|
29 (33.7)
|
52 (34)
|
|
Non-Hodgkin lymphoma
|
38 (56.7)
|
52 (60.5)
|
90 (59)
|
|
Multiple myeloma
|
2 (3.0)
|
0 (0)
|
2 (1%)
|
|
Other
|
4 (6.0)
|
3 (3.5)
|
7 (5%)
|
|
Spontaneous TLS
|
34 (50.7)
|
56 (65.1)
|
90 (59)
|
|
Risk of TLS
| | | |
|
Low risk
|
9 (13.4)
|
15 (17.4)
|
24 (16)
|
|
Intermediate risk
|
5 (7.5)
|
4 (4.7)
|
9 (6)
|
|
High risk
|
53 (79.1)
|
67 (77.9)
|
120 (78)
|
|
Cardiovascular risk
| | | |
|
Chronic hypertension
|
19 (28.4)
|
27 (31.4)
|
46 (30.1)
|
|
Diabetes
|
7 (10.4)
|
12 (14.0)
|
19 (12.4)
|
|
Cardiovascular event
|
5 (7.5)
|
10 (11.6)
|
15 (9.8)
|
|
Chronic kidney disease
|
6 (9.2)
|
4 (4.7)
|
10 (6.6)
|
|
HIV positive status
|
7 (10.4)
|
19 (22.1)
|
26 (17)
|
|
SOFA score
|
5.00 (3.00–8.00)
|
7.50 (5.00–12.00)
|
6.5 (4–9)
|
|
Vasopressors
|
1 (1.5)
|
21 (36)
|
24 (16)
|
|
Mechanical ventilation
|
5 (7.5)
|
29 (33.7)
|
34 (22.2)
|
|
Rasburicase use
|
54 (80.6)
|
60 (69.8)
|
114 (75)
|
|
Laboratory data at admission
| | | |
|
Kalemia, mEq/L
|
4.60 (4.00–5.00)
|
4.30 (3.90–5.00)
|
4.3 (3.9–5.0)
|
|
Phosphatemia, mg/dL
|
4.59 (3.61–6.08)
|
4.19 (3.08–5.94)
|
4.45 (3.41–5.88)
|
|
Calcemia, mg/dL
|
8.94 (7.90–9.50)
|
8.50 (7.84–9.45)
|
8.80 (8–9.60)
|
|
Uricemia, mg/dL
|
8.96 (5.64–13.10)
|
7.49 (5.12–12.16)
|
8.46 (5.23–12.41)
|
|
LDH, UI/L
|
2700 (1544–5168)
|
2855 (1544–5263)
|
2819 (1533–5169)
|
|
Delay admission-chemotherapy (days)
|
1 (0–7)
|
4 (0.5–12)
|
2.5 (0–11)
|
|
ICU mortality
|
0 (0)
|
27 (31.4)
|
27 (18)
|
|
One-year remission
|
54 (80.6)
|
0 (0.0)
|
54 (35.3)
|
- G6PD glucose 6 phosphate dehydrogenase, TLS tumor lysis syndrome, HIV human immunodeficiency virus, LDH lactate dehydrogenase, ICU intensive care unit
